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ORIGINAL ARTICLE
Comparison of the Prostate Imaging Reporting and  
Data System (PI-RADS) Version 1 and 2 in a Cohort  
of 245 Patients with Histopathological Reference and 
Long-Term Follow-Up
Pieter De Visschere, Eva Pattyn, Piet Ost, Tom Claeys, Nicolaas Lumen and 
Geert Villeirs
Objective: To compare the performance of PI-RADSv2 with PI-RADSv1 in patients with elevated PSA 
before biopsy.
Methods: 245 patients with elevated PSA underwent mpMRI before biopsy between May 2011 and 
December 2014 at 3.0 Tesla without endorectal coil. Patients underwent transrectal ultrasound-guided 
systematic 12-core biopsy followed by radical prostatectomy (N=68), radiation therapy (N=91) or clinical 
follow-up for at least two years (N=86). All exams were scored on a per-patient basis according to PI-
RADSv1 and PI-RADSv2. ClinsigPC was defined as Gleason score ≥7 (including 3+4 with prominent but not 
predominant Gleason 4 component), and/or tumour volume of ≥0.5cc, and/or tumour stage ≥T3a. 
Results: In 144 patients (58.8%) a ClinsigPC was found within two years after mpMRI. The PI-RADSv1 
and PI-RADSv2 overall assessment scores were significantly higher (P<0.001) in patients with ClinsigPC 
as compared to patients without ClinsigPC. ROC analysis showed an area under the curve of 0.82 (CI 
0.76–0.87) for PI-RADSv1 and 0.79 (CI 0.73–0.85) for PI-RADSv2 (P: NS). A threshold score of 3 exhibited 
sensitivities of 88.2% and 79.2% (P=0.001) and specificities of 64.4% and 67.3% (P: NS) with PI-RADSv1 
and PI-RADSv2, respectively.
Conclusions: The mpMRI scoring systems PI-RADSv1 and PI-RADSv2 yield similar accuracy to detect Clin-
sigPC in patients with elevated PSA, although clinicians should be aware that when an overall assessment 
score of 3 is used as a threshold for a positive mpMRI, PI-RADSv2 has lower sensitivity than PI-RADSv1. 
Nevertheless, PI-RADSv2 is preferable over PI-RADSv1 because it has the advantage of providing well-
defined instructions on how to determine the overall assessment category.
Keywords: Prostate neoplasms; Magnetic Resonance Imaging; Diffusion Weighted Imaging; MR  spectroscopic 
imaging; Prostate cancer
Introduction
Prostate cancer (PC) is the most frequent non-cutaneous 
tumor in men but up to 40% of PC will never cause symp-
toms or death and should be considered clinically insig-
nificant [1]. Multiparametric magnetic resonance imaging 
(mpMRI) has become an important imaging technique 
in the assessment of patients with known or suspected 
PC to detect or rule out clinically significant disease. In 
a mpMRI morphological T2-weighted imaging (T2-WI) are 
supplemented with diffusion-weighted imaging (DWI), 
dynamic contrast-enhanced imaging (DCE) and/or mag-
netic resonance spectroscopic imaging (MRSI) [2]. Report-
ing prostate mpMRI may be complex and prone to sub-
jective interpretation, therefore the European Society of 
Urogenital Radiology (ESUR) published in 2012 guidelines 
and proposed the Prostate Imaging Reporting and Data 
System version 1 (PI-RADSv1) [2].  The PI-RADSv1 scoring 
system involves assignment of separate scores to each of 
the modalities and provides explicit verbal descriptions 
on how to generate them. Each exam is assigned with 
an overall assessment score ranging from 1 (indicating 
that clinically significant cancer is highly unlikely to be 
present) to 5 (indicating that clinically significant can-
cer is highly likely to be present) to communicate the 
conclusion to the referring clinician. This overall assess-
ment category score is based on a subjective radiologist’s 
impression weighting the results of the single modalities. 
Whenever the results of the single scores are incoherent, 
one of the modalities is preferred over the others to gen-
erate the overall assessment score. PI-RADSv1 thus lacks 
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a  consistent  instruction on how to calculate the overall 
assessment score [2–4]. This shortcoming has resulted 
in the creation of a modified version in 2015, named PI-
RADS version 2 (PI-RADSv2) which was also adopted by the 
American College of Radiology (ACR)) [5, 6]. In PI-RADSv2 
two dominant modalities have been chosen, namely DWI 
for the peripheral zone (PZ) and T2-WI for the transition 
zone (TZ) and well-defined instructions have been pro-
vided on how to determine the overall assessment score. 
In the current study we aimed to compare the diagnos-
tic performance of PI-RADSv2 with PI-RADSv1 to detect 
clinically significant PC in patients with elevated PSA. We 
hypothesized that they were similar and in that case the 
previously established validation data of prostate mpMRI 
that were obtained using PI-RADSv1 might still be valid in 
the future for mpMRI that are performed using PI-RADSv2. 
Materials and Methods
Patients
All patients with elevated PSA who underwent prostate 
mpMRI before biopsy at our institution between May 2011 
and December 2014 were eligible for this study. Patient 
files were retrospectively explored to collect histopatho-
logical and clinical follow-up data as reference. Patients 
who had been treated for PC or had previous transurethral 
resection of the TZ as treatment of benign prostatic hyper-
plasia were excluded. Two-hundred and forty-five patients 
had adequate histopathological and clinical follow-up 
data for the purposes of this study. Patients were included 
if they underwent a systematic 12-core TRUS-guided pros-
tate biopsy followed by radical prostatectomy (N=68) or 
primary radiation therapy (N=91) within two years after 
the mpMRI. In all patients the presence of PC was ini-
tially established with a systematic 12-core TRUS-guided 
prostate biopsy. The biopsy cores were collected in eight 
separate containers: left and right prostate base, apex, 
midprostate and transition zone.  In patients treated by 
radical prostatectomy the histopathological conclusion of 
the prostatectomy specimen was used as the reference for 
the study instead of the biopsy result in case of discord-
ance (upgrading or downgrading). In the patients treated 
with primary radiation therapy the diagnosis relied solely 
on the prostate biopsy.  Patients not undergoing active 
treatment were included if they were followed up for at 
least two years with repetitive PSA measurements, digital 
rectal examination, TRUS-guided systematic 12-core pros-
tate biopsies and/or repeat mpMRI at the discretion of the 
referring urologist (N=86). In the latter group, 13 patients 
with a PC were followed in an active surveillance program. 
The remaining 73 patients had no evidence of tumor at 
initial biopsy and were without evidence of PC two years 
after the mpMRI. A patient was considered free of PC if for 
example the PSA value normalized spontaneously in the 
months after the MRI, or if repetitive TRUS biopsies were 
negative, or if a new mpMRI still showed no suspicious 
lesions. PC was considered clinically significant (ClinsigPC) 
if the Gleason score was ≥7 (including 3+4 with promi-
nent but not predominant Gleason 4 component), and/
or PC volume ≥0.5cc, and/or extraprostatic extension, 
as proposed in PI-RADSv2 (5).  The study was approved 
by our hospital’s Ethics Committee (EC 2011/495 with 
amendment dd. 18–11–2015).
mpMRI technique
The mpMRI consisted of T2-WI, DWI, DCE and MRSI and 
was performed at 3.0 Tesla without endorectal coil (Mag-
netom Trio, Siemens Medical Systems, Erlangen, Ger-
many). The acquisition parameters used for the study are 
presented in supplemental Table 1. 
All exams were anonymized and in January 2015 all 
mpMRI were evaluated according to the PI-RADSv1 and 
PI-RADSv2 scoring systems on a dedicated workstation 
(Leonardo, Siemens Medical Systems, Erlangen, Germany) 
by a single reader with 10 years of experience in pros-
tate mpMRI. The PI-RADSv1 and PI-RADSv2 scores were 
assigned strictly following the descriptions of the differ-
ent parameters in the respective guidelines. They were 
assigned during the same reading session because we 
wanted to avoid that a lesion was noted by the reader 
when scoring PI-RADSv1 but overlooked when scoring 
Histopathology and clinical diagnosis 
based on biopsy followed by:
N Gleason score T-stage clinsigPC
NC LG IG HG T1 T2 T3 T4 No Yes
Radical prostatectomy 68 1 5 33 29 0 44 23 0 3 65
Radiation therapy 91 0 18 26 47 28 40 20 3 14 77
Active surveillance > 2 years 13 0 11 2 0 13 0 0 0 11 2
>2 years of cancer free follow-up 73 73 / / / / / / / 73 0
Total 245 74 34 61 76 41 84 43 3 101 144
Table 1: Histopathological findings and clinical follow-up data.
NC: No prostate cancer.
LG: Low Grade Prostate Cancer, defined as prostate cancer with Gleason score 3+3 or lower.
IG: Intermediate Grade Prostate Cancer, defined as prostate cancer with Gleason score 3+4.
HG: High Grade Prostate Cancer, defined as any prostate cancer with primary Gleason grade 4 or any Gleason grade 5 
(including tertiary patterns).
ClinsigPC: Gleason score ≥7 (including 3+4 with prominent but not predominant Gleason 4 component), and/or 
 volume ≥0.5cc, and/or extraprostatic extension.
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PI-RADSv2 in a separate session. This would cause dif-
ferences between the scores that were not caused by the 
differences in the guidelines lexicon but caused by the 
reader. 
The image interpretation included an overall assessment 
category based on subjective weighting of the scores of 
the single modalities in PI-RADSv1 and based solely on the 
dominant modalities for PI-RADSv2 [2, 5]. We did not use 
the sum score for PI-RADSv1 as has been applied by sev-
eral researchers because this method was not mentioned 
nor recommended in the PI-RADSv1 guidelines. MRSI 
score was not taken into account for scoring PI-RADS v2. 
Statistical analysis
For statistical analysis, relationships between PI-RADSv1 
and PI-RADSv2 scores and the presence of ClinsigPC on 
a per-patient basis were assessed by the Mann-Whitney 
U-test. The balance between sensitivity and specificity for 
different thresholds was analyzed by receiver operating 
characteristic curves (ROC) and was conducted for the over-
all assessment categories and for the single mpMRI modal-
ity scores using the presence of ClinsigPC on a per-patient 
basis as the gold standard. The PI-RADSv1 and PI-RADSv2 
overall assessment categories were compared with the 
McNemar test. For the evaluation of the performance of 
PI-RADSv1 and PI-RADSv2 the scores were dichotomized 
in ‘negative’ in case of an overall assessment score of 1 or 
2 and ‘positive’ in case of a score 3, 4 or 5.  The level of 
significance was set at 0.05. For all statistical analyses SPSS 
for Windows version 22.0 (SPSS, Chicago, Ill) was used.
Results
In 144 patients (58.8%), a ClinsigPC was detected within 
two years following mpMRI. 
Histopathological and clinical follow-up data are dem-
onstrated in Table 1. The median age of the patients 
was 66 years old (range 44–85 years), PSA 9 µg/l (range 
1.4–935.5 µg/l) and prostate volume 49.3 cc (range 19.8–
201.0 cc). The overall assessment scores were significantly 
higher (P<0.001) in patients with ClinsigPC (median: 4, 
25th percentile: 3, 75th percentile: 5) as compared to 
patients without ClinsigPC, (median: 2, 25th percentile: 2, 
75th percentile 3) in both PI-RADSv1 and PI-RADSv2 indi-
cating that they are both useful scoring systems to provide 
relevant risk stratification of ClinsigPC.  
In PI-RADSv1 more patients were assigned an overall 
assessment score 3 (17.6% vs 10.2%) (P=0.005) and fewer 
a score 2 (28.6% vs 35.1%) (P=0.02) (Table 2) although 
the positive predictive values of the overall assessment 
scores were not statistically significantly different from 
PI-RADSv2.  An increase in probability of ClinsigPC was 
observed with increasing overall assessment score in 
both PI-RADSv1 and PI-RADSv2. An overall assessment 
score 5 had a positive predictive value for the presence of 
ClinsigPC of 90.4% when scored with PI-RADSv1 and 93.0 
% when scored with PI-RADSv2 (P= NS). 
The ROC analysis using the presence of ClinsigPC on 
a per patient base (Figure 1) showed an area under the 
curve (AUC) of 0.82 [95% CI, 0.76–0.87] for PI-RADSv1 
and 0.79 [95% CI, 0.73–0.85] for PI-RADSv2 (P= NS) indi-
cating clinically relevant predictive characteristics for both 
scoring systems. Evaluation of the separate mpMRI modal-
ities showed no significant differences in AUCs between 
PI-RADSv1 and PI-RADSv2 respectively for the scores of 
T2-WI in the PZ (0.78), T2-WI in the TZ (0.52 vs 0.53), DWI 
(0.82 vs 0.81) and DCE (0.81 vs 0.79) (P= NS) (Table 3). 
When an overall assessment score of 4 was used as a 
threshold for a positive mpMRI, the performance of 
Overall  
assessment  
score 
Frequency of assessed score Probability of ClinsigPC
PI-RADSv1 PI-RADsv2 P-value PI-RADSv1 PI-RADSv2 P-value
1 4.9% (12/245) 4.9% (12/245) NS 33.3% (4/12) 50.0% (6/12) NS
2 28.6% (70/245) 35.1% (86/245) 0.02 18.6% (13/70) 27.9% (24/86) NS
3 17.6% (43/245) 10.2% (25/245) 0.005 58.1% (25/43) 40.0% (10/25) NS
4 27.8% (68/245) 26.5% (65/245) NS 80.9% (55/68) 78.5% (51/65) NS
5 21.2% (52/245) 23.3% (57/245) NS 90.4% (47/52) 93.0% (53/57) NS
Table 2: Overall assessment scores and probability of clinically significant prostate cancer.
Figure 1: ROC curves of the overall assessment scores of 
PI-RADSv1 (green line, AUC 0.82 [95% CI 0.76–0.87]) 
and PI-RADSv2 (blue line, AUC 0.79 [CI 0.73–0.85]) 
using the presence of ClinsigPC on a per-patient basis 
as the reference.
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PI-RADSv1 and PI-RADSv2 was not significantly different, 
with accuracy of 75.5% and 76.3%, respectively (P=NS), 
sensitivity of 70.8% and 72.2% (P=NS) and specificity of 
both 82.2% (P=NS). When an overall assessment score of 
3 was used as a threshold for a positive mpMRI, the accu-
racy of PI-RADSv1 and PI-RADSv2 was not significantly 
different (78.4% vs 74.3%) (P=NS), but PI-RADSv1 showed 
significantly higher sensitivity than PI-RADSv2 (88.2% vs 
79.2%) (P=0.001) for similar specificity (64.4% vs 67.3%) 
(P=NS). 
The overall assessment scores of PI-RADSv1 and 
PI-RADSv2 were identical in 64.9% (159/245). With an 
overall assessment score of 3 as a threshold for a posi-
tive mpMRI, the dichotomized scores were concordant 
in 87.8% (215/245). In 46.1% (113/245) PI-RADSv1 and 
PI-RADSv2 were both true positive, in 24.1% (59/245) 
they were both true negative. In 27 patients (11.0%) 
PI-RADSv1 and PI-RADSv2 were both considered ‘false 
positive’ according to the definition of ClinsigPC that 
was used although actually in half of these cases (55.5%, 
15/27) a PC was present, but considered clinically insig-
nificant (a small Gleason 3+3 PC in 12 patients and a small 
Gleason 3+4 PC in 3 patients). In 16 patients (6.5%) a 
ClinsigPC was missed on both PI-RADSv1 and PI-RADSv2, 
but only a minority (5/16, 31.2%) were Gleason 4+3 PC 
or higher. 
With an overall assessment score of 3 as a threshold for 
a positive mpMRI, a discrepancy between the PI-RADSv1 
and PI-RADSv2 overall assessment scores occurred in 
12.2% (30/245) (Table 4). The main cause of this dis-
crepancy (46.7%, 14/30) were focal or diffuse suspi-
cious findings on T2-WI in the PZ with normal findings 
on DWI. They were scored positive with PI-RADSv1 but 
negative with PI-RADSv2 and in 71.4% (10/14) a ClinsigPC 
was present (Figure 2). Another cause (26.7%, 8/30) of 
discrepancy occurred in patients with focal suspicious 
contrast enhancement on DCE but with normal findings 
on all the other modalities (Figure 3). They were scored 
positive with PI-RADSv1 but negative with PI-RADSv2 
and in 37.5% (3/8) a ClinsigPC was present. A third cause 
(23.3%, 7/30) of discrepancy between PI-RADSv1 and 
PI-RADSv2 occurred when there was a suspicious lesion 
on T2-WI and DWI but without focal contrast enhance-
ment on DCE and normal metabolite concentrations on 
MRSI. They were scored negative with PI-RADSv1 but posi-
tive with PI-RADSv2 although a ClinsigPC was present in 
only 14.3% (1/7). An additional case of discrepancy was 
caused by a suspicious nodule in the TZ on DWI with 
contrast enhancement but with normal morphology on 
T2-WI, therefore scored positive with PI-RADSv1 but nega-
tive with PI-RADSv2 although a ClinsigPC was present 
(Figure 4).
Discussion
The present study demonstrated that in patients with 
elevated PSA both PI-RADSv1 and PI-RADSv2 were valid 
scoring systems for the risk stratification of ClinsigPC. The 
ROC analysis in our study exhibited AUC of 0.82 [95% CI, 
0.76–0.87] for PI-RADSv1 and 0.79 [95% CI, 0.73–0.85] 
for PI-RADSv2, which were similar to those reported in 
literature by Schimmöller [7] (AUC 0.81) and Portalez [8] 
(AUC 0.86) using PI-RADSv1 and by Muller [9] (0.86 for PZ, 
0.87 for TZ) using PI-RADSv2 indicating the ability of both 
standardized scoring systems to stratify mpMRI findings 
by cancer suspicion. When an overall assessment score 
of 4 was used as a cut-off level for a positive mpMRI, the 
performance of PI-RADSv1 and PI-RADSv2 was not signifi-
cantly different, but when a threshold of 3 was applied, 
then the sensitivity of scoring with PI-RADSv2 was lower 
than with PI-RADSv1. An overall assessment score of 3 
indicates that the presence of clinically significant disease 
is equivocal. This indeterminate mpMRI remains a prob-
lem and is currently still an important issue of debate. 
Nevertheless, in the clinical setting of mpMRI being per-
formed in patients with elevated PSA as additional param-
eter (next to clinical biomarkers such as PSA level, digital 
rectal examination and patient’s age) to decide to biopsy 
or not, an overall assessment score of 3 cannot exclude 
the presence of a clinsigPC with high enough certainty. 
Therefore it seems not prudent to omit or postpone the 
biopsy in these cases, and therefore most clinicians will 
consider a score 3 as a positive sign to perform a biopsy. 
The MRI findings are then still useful for targeting the 
equivocal area. Considering an overall assessment score 
3 as a positive mpMRI might lead to some overdiagnosis 
and clinicians should be aware that the decision to biopsy 
may then slightly be influenced by the scoring system that 
is used by the radiologist. It may be recommendable to 
discuss these cases at multidisciplinary meetings. With an 
overall assessment score of 3 as a threshold for a positive 
mpMRI a sensitivity and specificity of 88.2% and 64.4% 
respectively, were obtained with PI-RADSv1 and 79.2% 
mpMRI modality Area under the curve (95% confidence interval) P-value
PI-RADSv1 PI-RADSv2
Overall assessment score 0.82 (0.76-0.87) 0.79 (0.73-0.85) NS
T2-WI in PZ 0.78 (0.72-0.84) 0.78 (0.72-0.84) NS
T2-WI in TZ 0.52 (0.45-0.60) 0.53 (0.45-0.60) NS
DWI 0.82 (0.77-0.88) 0.81 (0.76-0.87) NS
DCE 0.81 (0.75-0.87) 0.76 (0.70-0.83) NS
MRSI 0,65 (0.58-0.72) / /
Table 3: AUC values of the ROC analysis for the overall assessment score and the different individual modalities.
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and 67.3%, with PI-RADSv2.  Our findings are consist-
ent with previously published results where sensitivities 
and specificities of 71–84% and 33–70% for PC of any 
grade, and of 80–90% and 47–61% for high-grade PC are 
reported with PI-RADSv1 [8, 10–20] and 88% and 71% in 
the PZ and 85% and 55% in the TZ with PI-RADSv2 [9]. 
Hamoen et al. [21] performed a meta-analysis of 14 
studies evaluating PI-RADSv1 and reported a wide vari-
ability in performance with a pooled sensitivity of 74% 
(95% CI 67%–81%) and a pooled specificity of 80% (95% 
CI 70%–88%) for studies with detection of  any PC as the 
outcome measure and a pooled sensitivity of 84% (95% CI 
76%–89%) and pooled specificity of 75% (95% CI 66%–
83%) for studies with detection of ClinsigPC as primary 
outcome. Rosenkrantz et al. [22]  performed an interob-
server reproducibility study of PI-RADSv2 and reported a 
sensitivity of 100% and specificity of 56.5% for detection 
of Gleason ≥3+4 PC with a score 3 as threshold for a posi-
tive mpMRI. These different results as compared to our 
study are probably related to the reference standard (MRI/
US fusion biopsy) that was used and a different clinical 
setting. It is likely that they have a high proportion of posi-
tive mpMRI while we tried to avoid too much (false) posi-
tive exams to avoid that otherwise on a per-patient basis 
no biopsies could be postponed or omitted.
Vargas et al. [23] investigated the impact of patho-
logic tumor volume on detectability with PI-RADSv2 and 
reported that PI-RADSv2 correctly identified 94–95% of 
PC foci of ≥0.5cc of any Gleason score but only 10–26% of 
PC foci with Gleason ≥4+3 but <0.5cc.
The dichotomized overall assessment scores of 
PI-RADSv1 and PI-RADSv2 in our study were concord-
ant in 87.8%, despite their differences in scoring of the 
individual modalities and determination of the overall 
assessment scores. In PI-RADSv1 some verbal descriptors 
showed imprecise results and were therefore modified 
when PI-RADSv2 was developed; for example, the scoring 
of DCE was a complex indicator in PI-RADSv1 because it 
PI-RADSv1 and  
PI-RADSv2  
discrepancy1
12,2% 
(30/245)
Overall assessment scores Histopathological 
findings
Reason  
discrepancy 
on mpMRI
N PI-
RADSv1
PI-
RADSv2
Missed ClinsigPC on 
PI-RADSv1 but true 
positive on PI-RADSv2
3,3% 
(1/30)
100% (1/1) 2 4 The ClinsigPC was a 
large Gleason 3+3 PC
T2-WI and DWI 
 suspicious, but DCE 
and MRSI normal
True negative on  
PI-RADSv1 but false 
positive on PI-RADSv2
20,0% 
(6/30)
83,3% (5/6) 2 3 No ClinsigPC: no 
cancer in 4 cases, but 
a small Gleason 3+3 
PC in 1 case
In all cases T2-WI and 
DWI suspicious, but 
DCE and MRSI normal
16,7% (1/6) 2 4 No ClinsigPC 
although there was 
a very small Gleason 
3+4 PC
False positive on  
PI-RADSv1 but true 
negative on PI-RADSv2
30,0% 
(9/30)
11,1% (1/9) 3 1 No cancer In 5 cases DCE 
 suspicious but all 
other modalities 
normal and in 4 cases 
T2-WI suspicious but 
DWI normal in PZ
77,8% (7/9) 3 2 No ClinsigPC 
although there was 1 
case of small Gleason 
3+3 PC, 2 cases of 
HGPIN & BCH and 1 
case of ASAP
11,1% (1/9) 4 2 No cancer
True positive on  
PI-RADsv1 but missed 
ClinsigPC on PI-RADSv2
46,7% 
(14/30)
7,1% (1/14) 3 1 The ClinsigPC was a 
Gleason 4+3 PC
In 3 cases DCE 
 suspicious but all 
other modalities 
normal, in 10 cases 
T2-WI suspicious but 
DWI normal in PZ and 
in 1 case only DWI 
suspicious in TZ
78,6% (11/14) 3 2 The ClinsigPC were 1 
Gleason 3+3 pT2c, 6 
Gleason 3+4 PC and 
4 Gleason 4+3 PC or 
higher
7,1% (1/14) 4 2 The ClinsigPC was a 
Gleason 3+4 PC
7,1% (1/14) 5 2 The ClinsigPC was a 
Gleason 3+4 PC
Table 4: Discrepancies between PI-RADSv1 and PI-RADSv2.
1After dichotomization with considering an overall assessment score 1 and 2 as ‘negative’ and 3, 4 or 5 as ‘positive’ 
mpMRI.
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Figure 2: A 63-year-old man with a PSA of 6.3 µg/L. On T2-WI (a) in the PZ an ill-defined low signal intensity focus is 
present posteriorly on the left side in the prostate base (white oval) (PI-RADSv1 score 4; PI-RADSv2 score 4). On DWI 
the signal intensity on ADC is high (b) and on high-b-value image isointense/mildly hyperintense (c) (PI-RADSv1 
score 1; PI-RADSv2 score 1). On DCE (4) the area shows strong contrast enhancement (white oval) (PI-RADSv1 score 
4; PI-RADSv2 negative). With the PI-RADSv1 scoring system this patient was assigned an overall assessment score 4, 
based on a subjective impression of the findings on T2-WI and DCE. With the PI-RADSv2 scoring system, this patient 
was assigned an overall assessment score of 1 since DWI is the dominant modality in the PZ. A prostate biopsy fol-
lowed by radical prostatectomy in this patient showed however a Gleason 3+4 prostate cancer on the left side in the 
PZ of the prostate base.
Figure 3: A 66-year-old man with PSA 9.8µg/L. On T2-WI (a) the PZ shows diffuse mild hypointensity, with indistinct 
margin (PI-RADSv1 score3; PI-RADSv2 score 3). On DWI the PZ shows high ADC values (b) and is isointense on high-
b-value image (c) (PI-RADSv1 score 1; PI-RADSv2 score 1). On DCE there is a focal enhancing lesion posterolateral 
on the right side in the PZ (black star) (PI-RADSv1 score 4; PI-RADSv2 positive). With the PI-RADSv1 scoring system, 
this patient was assigned an overall assessment score 4, based on a subjective overall impression of the findings in 
all modalities. With the PI-RADSv2 scoring system this patient was assigned an overall assessment score 1 because 
DWI was scored 1 and this is the dominant modality in PZ. Prostate biopsy followed by radical prostatectomy in this 
patient showed a Gleason 3+4 prostate cancer on the right side in the PZ.
De Visschere et al: Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and 2 
in a Cohort of 245 Patients with Histopathological Reference and Long-Term Follow-Up
Art. X, pp.  7 of 10 
combined a 3-point score with additional points [2, 8, 
17, 18]. The modified verbal descriptions in PI-RADSv2 
resulted in our study in different scoring of individual 
modalities between PI-RADSv1 and PI-RADSv2, but this 
had in the majority of cases no impact when dichoto-
mizing the scores in positive (score 3, 4 or 5) or nega-
tive (score 1 or 2). For example, a very suspicious lesion 
of <1.5cm in the PZ on DWI was assigned a score 5 in 
PI-RADSv1 but a score 4 in PI-RADSv2 (Figure 5); both 
were considered positive and supported the clinician’s 
decision to biopsy.
In PI-RADSv2 fewer patients were assigned an overall 
assessment score 3 as compared with PI-RADSv1 (10.2% vs 
17.6%), with a shift mainly to an overall assessment score 
2 (35.1% vs 28.6%). Discrepancy between the PI-RADSv1 
and PI-RADSv2 overall assessment score occurred mainly 
in patients with focal or diffuse suspicious findings in 
the PZ on T2-WI but with normal findings on DWI, or in 
patients with focal suspicious contrast enhancement on 
DCE but with normal findings on all the other modalities: 
they were all scored positive with PI-RADSv1 but nega-
tive with PI-RADSv2. The AUCs for the T2-WI scores, DWI 
and DCE scores were not significantly different between 
PI-RADSv1 and PI-RADSv2, thus the shift in overall assess-
ment scores from 3 to 2 was not caused by differences in 
the scoring of the individual modalities but was the result 
of a different way of generating the overall assessment 
scores.
PI-RADSv1 lacked a consistent instruction on how to 
weight the scores given to the individual sequences and 
how to calculate the overall assessment score [1, 3]. The 
complexity and sometimes contradictory findings of the 
different single modalities resulted in substantial hetero-
geneity in interpretations of mpMRI in routine clinical 
practice between institutions and in the analysis and cut-
off values used in the PI-RADSv1 scores [21]. Some authors 
[3, 8, 18] added the individual scores of each sequence to 
a total sum score to generate the overall PI-RADSv1 score, 
based on the assumption that all the modalities had the 
same diagnostic weight. Variable performances were 
reported with this arithmetic sum score as compared to 
the subjective radiologist’s impression approach [3, 8, 12, 
20, 21, 24]. It may seem intuitive to use this method, but 
it was not mentioned nor recommended in the PI-RADSv1 
guidelines. Moreover, the sum score is not necessar-
ily the best option to compare between institutions a 
PI-RADSv1 score on a 4–20 scale (when MRSI is included) 
with a PI-RADSv1 score on a 3–15 scale (when MRSI is not 
included because it is an optional technique) or with a 
PI-RADSv2 on a 1–5 scale.
PI-RADSv2 has overcome this problem by assigning 
strict criteria on how to determine the overall assess-
ment category. It was hoped that this would make the 
interpretation of the PI-RADS score easier, especially for 
less experienced readers, but Muller et al. [9] reported 
that PI-RADSv2 had only moderate level of interobserver 
Figure 4: A 56-year-old man with PSA of 11.2µg/L. On T2-WI (a) the PZ shows a homogenous high signal intensity 
(PI-RADSv1 score 1; PI-RADSv2 score 1) and in the TZ a well-margined homogenous hypointense area is noted (PI-
RADSv1 score 2; PI-RADSv2 score 2). On DWI this area in the TZ shows low ADC value (b) (white star) and is isoin-
tense on high-b-value image (c) (PI-RADSv1 score 4; PI-RADSv2 score 4). On DCE this area shows strong contrast 
enhancement (black star) (PI-RADSv1 score 4; PI-RADSv2 positive). With the PI-RADSv1 scoring system this patient 
was assigned an overall assessment score 4, based on a subjective overall impression of the findings in all modalities. 
With the PI-RADSv2 scoring system, T2-WI in the TZ was scored 2, and since T2-WI is the dominant modality in the TZ 
the overall assessment score was also 2. Prostate biopsy followed by radical prostatectomy in this patient showed a 
Gleason 3+4 prostate cancer in the TZ.
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agreement for readers of varying experience, similar as for 
PI-RADSv1 [25]. 
In summary, PI-RADSv1 and PI-RADSv2 yield similar 
accuracy although a reduction in sensitivity was noted 
when using PI-RADSv2 with an overall assessment score 
of 3 as a threshold. Nevertheless, the advantage of 
PI-RADSv2 to provide well-defined instructions on how 
to determine the overall assessment category is prefer-
able over PI-RADSv1 with its subjective overall impres-
sion method. Further research is necessary to improve the 
scoring system, and we would like to suggest some modi-
fications that may be taken into account when working 
towards a PI-RADS version 3. In our study we noted a shift 
from overall assessment score 3 with PI-RADSv1 to score 
2 when using PI-RADSv2, not caused by the assessment of 
the individual modalities but due to the different way of 
generating the overall assessment category. The majority 
of these discrepancies were caused by a suspicious lesion 
in the PZ on T2-WI but with normal DWI, scored positive 
with PI-RADSv1 but negative with PI-RADSv2 although a 
ClinsigPC was actually present in about 60%. Therefore, 
we suggest that the rules for determination of the overall 
assessment score might be adapted or clarified; for exam-
ple, a weighting factor for each modality could be included 
in order to make it possible that a very suspicious lesion in 
T2-WI in the PZ could overrule a negative DWI. 
There are some limitations to our study. Firstly, we did 
not have step-section histopathology of radical prostatec-
tomy specimens as gold standard in all patients. Studies 
using only RP specimens as the reference standard may 
however show selection bias by exclusion of men with 
negative biopsy or patients not suitable for RP. In our 
study 91 patients (37.1%) treated with radiation therapy 
were included although the diagnosis in these patients 
relies solely on prostate biopsy. It may be estimated 
that about 20% of these patients who were treated for 
a low-grade PC might have harbored high-grade PC that 
remained undetected [26].  Also, in the patients that 
were considered free of cancer there is no perfect way to 
prove the absence with 100 % certainty. We considered a 
minimum of two years of follow-up as a reasonable time 
for a life-threatening ClinsigPC that might have been 
present at time of the MRI to appear. Secondly, our histo-
pathological and clinical follow-up reference was deter-
mined on a per-patient basis, thus correlation of the 
PI-RADS scores with regional location of the PC in the 
prostate was not possible. We have chosen to evaluate 
the scoring systems in the most relevant setting for cli-
nicians in daily practice because the overall assessment 
score will eventually be communicated in the report as 
a simplified risk-stratification system providing recom-
mendations for further diagnostic procedures. Thirdly, 
Figure 5: A 63-year-old man with PSA 8.35 µg/L. In the PZ on the left side there is a low signal intensity focus on T2-WI 
(PI-RADSv1 score 5; PI-RADSv2 score 4) (a) (white star) with restricted diffusion (markedly hypointense on ADC (b) 
and hyperintense on high-b-value (c)) (PI-RADSv1 score 5, PI-RADSv2 score 4). The size of the lesion is <1,5 cm, it 
has no broad contact with the prostate capsule and shows no definite extraprostatic extension. On DCE (d) it shows 
strong contrast enhancement (black star) (PI-RADSv1 score 5; PI-RADSv2 positive). The overall assessment score is 
5 when using PI-RADSv1 based on a subjective impression of the findings of all modalities and is 4 in PI-RADSv2 
based on the DWI-only which should be given a score 4. Despite the different overall assessment category between 
PI-RADSv1 and PI-RADSv2 the message to the clinician is the same, i.e. targeted prostate biopsy is warranted. Prostate 
biopsy followed by radical prostatectomy confirmed a PC with Gleason score 3+4 = 7 (with tertiary pattern 5).
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the PIRADSv1 and PIRADSv2 scores were assigned by a 
single reader during the same reading session, and not 
in a blinded manner. This may have induced homogeni-
zation of the scores, but was necessary for the purpose 
of the study, which was to compare the scores, not to 
evaluate the reader. 
We did not compare the inter- and intra-observer vari-
ability of PI-RADSv1 and PI-RADSv2 in the current study, 
but this may be an interesting topic for future research. A 
last limitation may be the definition used for ClinsigPC in 
our study. Unfortunately, there is currently a lack of con-
sensus among urologists about what constitutes clinically 
significant disease, therefore we decided to use the defini-
tion as proposed in PI-RADSv2 [5], although we are aware 
that other definitions might have resulted in different 
performance characteristics.
Conclusion
The mpMRI scoring systems PI-RADSv1 and PI-RADSv2 
yield similar accuracy to detect ClinsigPC in patients with 
elevated PSA, although clinicians should be aware that 
when an overall assessment score of 3 is used as a thresh-
old for a positive mpMRI, PI-RADSv2 has lower sensitiv-
ity than PI-RADSv1. Nevertheless, PI-RADSv2 is preferable 
over PI-RADSv1 because it has the advantage of providing 
well defined instructions on how to determine the overall 
assessment category.
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